This webcast is part of the continuing education program for Heath Care Professionals. (Duration: 1h)
Surgery, chemotherapy, and radiation have been the foundation of cancer treatment for decades. Cancer researchers are now studying how harnessing the immune system can help destroy cancer cells. One type of immunotherapy involves engineering patients’ own T-cells to have a unique receptor, called a chimeric antigen receptor (CAR), enabling these immune cells to recognize and attack cancer cells. CAR T-cell therapy is currently used for some types of blood cancers and in development for hundreds of other cancers types. In this presentation, Dr. Mona Shafey will present how a CAR T-cell is made and how it works, as well as the current and future indications for this novel therapy.
Dr. Mona Shafey is a Clinical Associate Professor in the Division of Hematology and Hematological Malignancies. She completed medical school and residency training at the University of Ottawa and completed fellowship training in stem cell transplantation at the University of Calgary. Her clinical and research interests focus on malignant hematology, particularly lymphoma and CLL, and the use of stem cell transplantation for those diseases. She has also completed a Medical Education Certificate program through the University of Dundee and is the Program Director for the Adult Hematology Residency Training Program at the University of Calgary and is quite involved in the education of future physicians.
This webcast was made possible thanks to the support of: